Back to School: How biopharma can reboot drug development. Access exclusive analysis here
BioMarin (BMRN; SWX:BMRN) and partner Genzyme (GENZ) reported six-month extension data from a previously reported Phase III trial in 45 patients with
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury